Tissue-inhibitors of metalloproteinase-1 and vascular-endothelial growth-factor in severe haemophilia A children on low dose prophylactic recombinant factor VIII: Relation to subclinical arthropathy.

Nevine Gamal AndrawesHossam Mousa SakerNouran Yousef Salah El-DinMervat Abd Elhakim Hussain

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2020)

Vascular endothelial growth factor and TIMP-1 can be used for early detection of HA. Further prospective studies should include larger study populations. In addition, studies should address the role of various anti-VEGFs as potential therapy for HA and their impact on prevention and treatment of HA.

Keyphrases

vascular endothelial growth factor
low dose
endothelial cells
case control
young adults
cell free
drug induced
climate change
genetic diversity